Pacific Shores Medical Group
Phone:    562-590-0345
​Toll Free: 855-590-0345
  • Home
  • Our Physicians
  • Our NPs and PAs
  • Research Program
  • Hospital Affiliations
  • Insurance Plans
  • Office Locations
    • Glendale
    • Huntington Beach
    • Irvine
    • Long Beach Elm
    • Long Beach Worsham
    • Newport Beach
  • Office Information
    • Office Brochures
    • Espanol
    • Chinese
  • New Patient Information
  • PET Scan
  • Resources
  • Blog
  • Patient Portal

Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

5/14/2018

 
PictureSarmen Sarkissian, MD
Durvalumab is an FFP—L1 monoclonal antibody that has been approved and metastatic or unresectable urothelial carcinoma.  It has also been approved in the adjuvant setting for nonresectable non-small cell lung cancer.  It phase I—phase II clinical trial of locally advanced or metastatic urothelial carcinoma, Dr Powles reported in JAMA Oncology, on 191 patients.  Patients are treated with the antibody at 10 mg/kg.  He was administered every 2 weeks for up to 12 months or until disease progression.  Patient’s either refusal was not eligible for first line chemotherapy.  Median age was 67 years old.  71% of patients will none.  All had stage IV disease.  99% had prior treatment.  At a median follow-up of 6 months, the objective response rate 70.8%.  Complete responses were seen in 7 patients.  Median time to response was nearly 1-1/2 months.  Median duration of response was not reached with more than 17 patient’s sustaining a response greater than 6 months.  77% of responders have an ongoing response at the clinical.  Only 7% of patients had grade 3 or 4-related toxicity.
 
https://jamanetwork.com/journals/jamaoncology/article-abstract/2648865?redirect=true


Picture

Comments are closed.

    News From PSMG

    The latest news at Pacific Shores Medical Group

    Archives

    December 2018
    June 2018
    May 2018
    August 2017
    July 2017
    June 2017
    March 2014
    November 2013
    August 2013
    April 2013
    March 2013
    January 2013

    Categories

    All
    Breast Cancer
    Immunotherapy
    Lung Cancer
    Lymphoma
    Multiple Myeloma
    Prostate Cancer

    RSS Feed

    Disclaimer: This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, Pacific Shores Medical Group provides general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. Pacific Shores Medical Group is not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site.
Home    Disclaimer   Contact Us
Office Locations -  Glendale  -  Huntington Beach  -  Irvine  -  Long Beach Elm  -  Long Beach Worsham - Newport Beach -
© 2018 Pacific Shores Medical Group